[1]敖 劲,杨孔武,穆茂媛,等.微粒-TACE联合伊马替尼治疗进展期胃肠道间质瘤肝转移临床疗效观察[J].介入放射学杂志,2020,29(08):820-823.
AO Jin,YANG Kongwu,MU Maoyuan,et al.TACE with gelatin sponge microparticles combined with imatinib for liver metastases from advanced gastrointestinal stromal tumors: clinical observation of curative effect[J].journal interventional radiology,2020,29(08):820-823.
点击复制
微粒-TACE联合伊马替尼治疗进展期胃肠道间质瘤肝转移临床疗效观察()
《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]
- 卷:
-
29
- 期数:
-
2020年08
- 页码:
-
820-823
- 栏目:
-
临床研究
- 出版日期:
-
2020-08-25
文章信息/Info
- Title:
-
TACE with gelatin sponge microparticles combined with imatinib for liver metastases from advanced gastrointestinal stromal tumors: clinical observation of curative effect
- 作者:
-
敖 劲; 杨孔武; 穆茂媛; 石明涛; 利 峰; 蔡 争; 杨明镇; 石荣书
-
- Author(s):
-
AO Jin; YANG Kongwu; MU Maoyuan; SHI Mingtao; LI Feng; CAI Zheng; YANG Mingzhen; SHI Rongshu.
-
Department of Interventional Radiology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province 563003, China
-
- 关键词:
-
【关键词】 肝动脉灌注化疗栓塞; 胃肠间质瘤; 肝转移瘤; 伊马替尼
- 文献标志码:
-
A
- 摘要:
-
【摘要】 目的 评估应用明胶海绵微粒TACE(GSM-TACE)联合伊马替尼治疗进展期胃肠道间质瘤(GIST)肝转移的临床疗效及安全性 方法 2013年1月—2019年1月收治9例不能外科手术的胃肠道间质瘤肝转移患者,规律服用伊马替尼治疗进展后,选用GSMs-TACE联合伊马替尼治疗,对患者的临床资料,CT随访结果,介入治疗的并发症及预后等情况进行总结和分析。术后采用改良实体瘤评价标准(mRECIST)标准评估疗效,术后每月随访1次。结果 9例GIST肝转移均为接受伊马替尼治疗6~30个月进展的患者,且无外科根治性手术指征;9例患者共接受17次GSM-TACE治疗;根据mRECIST评价标准,完全缓解(CR)4例,部分缓解(PR)5例;中位生存时间(24±4.4)个月;无肝脓肿形成,未发生与介入相关的严重并发症。结论 GMS-TACE联合伊马替尼治疗胃肠道间质瘤肝转移是一种安全的、有效的治疗方法。
参考文献/References:
[1] Tryggvason G, Gislason HG, Magnusson MK, et al. Gastroin-testinal stromal tumors in Iceland, 1990- 2003: the icelandic GIST study, a population- based incidence and pathologic risk stratification study[J]. Int J Cancer, 2005, 117:289- 293.
[2] Shi YN, Li Y, Wang LP, et al. Gastrointestinal stromal tumor(GIST) with liver metastases. An 18- year experience from the GIST cooperation group in North China[J]. Medicine(Baltimore),2017,96:e8240.
[3] Caram MV, Schuetze SM. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options[J]. J Surg Oncol, 2011, 104: 888- 895.
[4] 中国CSCO胃肠间质瘤专家委员会. 中国胃肠间质瘤诊断治疗专家共识(2011年版)[J]. 中华胃肠外科杂志, 2012, 15:301- 307.
[5] Kobayashi K, Gupta S, Trent JC, et al. Hepatic artery chemoem- bolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors[J]. Cancer, 2006, 107: 2833- 2841.
[6] Kobayashi K, Szklaruk J, Trent JC, et al. Hepatic arterial embolization and chemoembolization for imatinib- resistant gastrointestinal stromal tumors[J]. Am J Clin Oncol, 2009, 32:574- 581.
[7] Cao G, Li J, Shen L, et al. Transcatheter arterial chemoem-bolization for gastrointestinal stromal tumors with liver metastases[J]. World J Gastroenterol, 2012, 18: 6134- 6140.
[8] Cao G, Zhu X, Li J, Guo J, et al. A comparative study between Embosphere?誖and conventional transcatheter arterial chemoembo- lization for treatment of unresectable liver metastasis from GIST[J]. Chin J Cancer Res, 2014, 26:124- 131.
[9] Chen YY, Yeh CN, Cheng CT, et al. Sunitinib for taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance[J]. World J Gastroenterol, 2011, 17: 2113- 2119.
[10] Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of gorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib(GRID): aninternational,multi- centre,randomised,placebo- controlled,phase 3 trial[J]. Lancet, 2013, 381: 295- 302.
[11] 林钧华,刘鲁明,周振华. 胃肠道间质瘤肝转移介入治疗疗效分析[J]. 介入放射学杂志, 2006, 15:283- 285.
[12] Maluccio MA, Covey AM, Schubert J, et al. Treatment of metastatic sarcoma to the liver with bland embolization[J]. Cancer, 2006, 107: 1617- 1623.
[13] Stampfl S, Bellemann N, Stampfl U, et al. Arterial distribution characteristics of embozene particles and comparison with other spherical embolic agents in the porcine acute embolization model[J]. J Vasc Interv Radiol, 2009, 20: 1597- 1607.
备注/Memo
- 备注/Memo:
-
(收稿日期:2019- 07- 01)
(本文编辑:俞瑞纲)
更新日期/Last Update:
2020-08-17